ADORA2BP1

Across TCGA pan-cancer cohorts, ADORA2BP1 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of ADORA2BP1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where ADORA2BP1 RNA is repressed in tumor relative to normal tissue. In most cancer types ADORA2BP1 is over-expressed in tumor, although a few such as KIRP and KIRC show the opposite, repressed pattern.

KIRP, KIRC, and KICH are the cancer types where ADORA2BP1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ADORA2BP1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	Male	II,III,IV	−1.911	<.001	11	view →
KIRC	Male	All	−1.039	<.001	9	view →
KICH	All	II,III,IV	−1.136	<.001	7	view →
BRCA	All	II,III,IV	−0.328	<.001	6	view →
LIHC	Female	II,III,IV	−1.665	<.001	5	view →
STAD	All	All	+0.118	<.001	4	view →
CHOL	Female	All	−2.660	<.001	3	view →
THCA	All	III,IV	−0.051	.009	3	view →
COAD	All	II,III,IV	+0.125	.016	2	view →
PRAD	All	All	−0.097	.041	2	view →
LUAD	All	All	−0.090	.046	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

ADORA2BP1–KIRP

Open the KIRP breakdown →